Effects of Herstatin, an Alternative HER-2 (erbB-2) Product, on Hormonal Responsiveness of Breast Cancer
Abstract
The HER-2 receptor tyrosine kinase (erbB-2) and the estrogen receptor (ER) participate in the establishment and progression of breast cancer. While the anti-estrogen tamoxifen is used as a therapeutic resistance is a clinical problem. Over expression of HER-2 confers resistance to the antiestrogen tamoxifen. The objective was to evaluate the effects of Herstatin a naturally occurring inhibitor of the HER-2 receptor on hormonal responsiveness of breast cancer cells. scope. The effects of Herstatin were tested on MCF-7 and McF-7/HER-2 breast carcinoma cells by stable transfection or treatment with Herstatin in the presence or absence of estrogen. There was no effect of Herstatin on hormonal response of MCF-7 cells with low levels of HER-2 in vivo or in vitro. In McF-7/HER-2 cells, Herstatin enhanced response to estrogen and depressed levels of HER-3. These studies suggest that Herstatin has no effect on hormonal response of MCF7 cells with low levels of HER-2 but may restore hormonal response to breast cancer cells that overexpressHER-2.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2006
- Accession Number
- ADA468526
Entities
People
- Gail M. Clinton
Organizations
- Oregon Health & Science University